{"id":"drug-dose-sm-88","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5308436","moleculeType":null,"molecularWeight":"1121.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SM-88 works by disrupting the metabolic pathways that cancer cells depend on for survival and proliferation, particularly targeting glycolysis and amino acid metabolism. By inhibiting these metabolic processes, the drug aims to starve cancer cells of the energy and building blocks they need to grow. This metabolic approach is designed to work synergistically with standard chemotherapy agents.","oneSentence":"SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:03.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel)"}]},"trialDetails":[{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT02796898","phase":"PHASE1, PHASE2","title":"Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Tyme, Inc","startDate":"2016-06","conditions":"Prostate Cancer, Rising Prostate Specific Antigen (PSA)","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Drug: Dose -SM-88","genericName":"Drug: Dose -SM-88","companyName":"Pancreatic Cancer Action Network","companyId":"pancreatic-cancer-action-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization. Used for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}